Substantial Antiviral Potential of Deoxyribozymes Fixed on Anatase Nanoparticles Against Influenza A Viruses in vitro and in vivo

J Pharm Sci. 2024 May;113(5):1202-1208. doi: 10.1016/j.xphs.2023.10.028. Epub 2023 Oct 23.

Abstract

Influenza A viruses (IAV) are a high threat to humanity because of a lack of proper effective antiviral drugs and resistance of viruses to existing vaccines. We describe the sufficient anti-IAV effect of Ans/PL-Dz nanocomposites that contain deoxyribozymes (Dz) immobilized on anatase TiO2 nanoparticles (Ans) through polylysine linker (PL). The Dz-containing nanocomposites appear to be more efficient than the Ans/PL-ODN nanocomposites that contain common oligodeoxyribonucleotides (ODN) targeted to the same RNA regions of the viral genome. The simultaneous use of nanocomposites that contain Dz and ODN, which are targeted to different sites of viral RNA provides a higher overall effect than the independent action of each of them (synergism). The inhibition of IAV with the proposed nanocomposites was shown to be effective, sequence-specific, and dose-dependent. The most efficient Ans/PL-Dz nanocomposite exhibited a high antiviral effect in vivo on mice models. The efficiency of IAV inhibition with this nanocomposite in vitro and in vivo is higher than that for the approved antiflu drug oseltamivir. The results open the prospect of creating a unique antiviral agent suitable for IAV suppression.

Keywords: Antiviral effect; Deoxyribozymes; Influenza A virus; Nanocomposites.

MeSH terms

  • Animals
  • Antiviral Agents / pharmacology
  • DNA, Catalytic* / pharmacology
  • DNA, Catalytic* / therapeutic use
  • Dogs
  • Humans
  • Influenza A virus* / genetics
  • Influenza, Human* / drug therapy
  • Madin Darby Canine Kidney Cells
  • Mice
  • Nanoparticles*
  • Titanium*

Substances

  • Antiviral Agents
  • DNA, Catalytic
  • titanium dioxide
  • Titanium